Papilledema: epidemiology, etiology, and clinical management

Mohammed Rigi,1 Sumayya J Almarzouqi,2 Michael L Morgan,2 Andrew G Lee2–4 1Robert Cizik Eye Clinic, University of Texas, 2Department of Ophthalmology, Houston Methodist Hospital, Blanton Eye Institute, 3Baylor College of Medicine, 4Departments of Ophthalmology, Neurology, and Neurosurgery,...

Full description

Bibliographic Details
Main Authors: Rigi M, Almarzouqi SJ, Morgan ML, Lee AG
Format: Article
Language:English
Published: Dove Medical Press 2015-08-01
Series:Eye and Brain
Online Access:http://www.dovepress.com/papilledema-epidemiology-etiology-and-clinical-management-peer-reviewed-article-EB
_version_ 1818549695277957120
author Rigi M
Almarzouqi SJ
Morgan ML
Lee AG
author_facet Rigi M
Almarzouqi SJ
Morgan ML
Lee AG
author_sort Rigi M
collection DOAJ
description Mohammed Rigi,1 Sumayya J Almarzouqi,2 Michael L Morgan,2 Andrew G Lee2–4 1Robert Cizik Eye Clinic, University of Texas, 2Department of Ophthalmology, Houston Methodist Hospital, Blanton Eye Institute, 3Baylor College of Medicine, 4Departments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medical College, Houston, UTMB Galveston, UT MD Anderson Cancer Center, Houston, TX, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA Abstract: Papilledema is optic disc swelling due to high intracranial pressure. Possible conditions causing high intracranial pressure and papilledema include intracerebral mass lesions, cerebral hemorrhage, head trauma, meningitis, hydrocephalus, spinal cord lesions, impairment of cerebral sinus drainage, anomalies of the cranium, and idiopathic intracranial hypertension (IIH). Irrespective of the cause, visual loss is the feared morbidity of papilledema, and the main mechanism of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow stasis. Treatment is directed at correcting the underlying cause. In cases where there is no other identifiable cause for intracranial hypertension (ie, IIH) the available options include both medical and surgical modalities. Weight loss and diuretics remain the mainstays for treatment of IIH, and surgery is typically reserved for patients who fail, are intolerant to, or non-compliant with maximum medical therapy. Keywords: papilledema, intracranial hypertension, idiopathic intracranial hypertension, epidemiology, papilledema management, papilledema etiology, acetazolamide, optic nerve sheath fenestration, ventriculoperitoneal shunt, lumboperitoneal shunt, venous sinus stenting
first_indexed 2024-12-12T08:36:42Z
format Article
id doaj.art-2178ce80af984c2484979dfc24e00aac
institution Directory Open Access Journal
issn 1179-2744
language English
last_indexed 2024-12-12T08:36:42Z
publishDate 2015-08-01
publisher Dove Medical Press
record_format Article
series Eye and Brain
spelling doaj.art-2178ce80af984c2484979dfc24e00aac2022-12-22T00:30:54ZengDove Medical PressEye and Brain1179-27442015-08-012015default475723178Papilledema: epidemiology, etiology, and clinical managementRigi MAlmarzouqi SJMorgan MLLee AGMohammed Rigi,1 Sumayya J Almarzouqi,2 Michael L Morgan,2 Andrew G Lee2–4 1Robert Cizik Eye Clinic, University of Texas, 2Department of Ophthalmology, Houston Methodist Hospital, Blanton Eye Institute, 3Baylor College of Medicine, 4Departments of Ophthalmology, Neurology, and Neurosurgery, Weill Cornell Medical College, Houston, UTMB Galveston, UT MD Anderson Cancer Center, Houston, TX, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA Abstract: Papilledema is optic disc swelling due to high intracranial pressure. Possible conditions causing high intracranial pressure and papilledema include intracerebral mass lesions, cerebral hemorrhage, head trauma, meningitis, hydrocephalus, spinal cord lesions, impairment of cerebral sinus drainage, anomalies of the cranium, and idiopathic intracranial hypertension (IIH). Irrespective of the cause, visual loss is the feared morbidity of papilledema, and the main mechanism of optic nerve damage is intraneuronal ischemia secondary to axoplasmic flow stasis. Treatment is directed at correcting the underlying cause. In cases where there is no other identifiable cause for intracranial hypertension (ie, IIH) the available options include both medical and surgical modalities. Weight loss and diuretics remain the mainstays for treatment of IIH, and surgery is typically reserved for patients who fail, are intolerant to, or non-compliant with maximum medical therapy. Keywords: papilledema, intracranial hypertension, idiopathic intracranial hypertension, epidemiology, papilledema management, papilledema etiology, acetazolamide, optic nerve sheath fenestration, ventriculoperitoneal shunt, lumboperitoneal shunt, venous sinus stentinghttp://www.dovepress.com/papilledema-epidemiology-etiology-and-clinical-management-peer-reviewed-article-EB
spellingShingle Rigi M
Almarzouqi SJ
Morgan ML
Lee AG
Papilledema: epidemiology, etiology, and clinical management
Eye and Brain
title Papilledema: epidemiology, etiology, and clinical management
title_full Papilledema: epidemiology, etiology, and clinical management
title_fullStr Papilledema: epidemiology, etiology, and clinical management
title_full_unstemmed Papilledema: epidemiology, etiology, and clinical management
title_short Papilledema: epidemiology, etiology, and clinical management
title_sort papilledema epidemiology etiology and clinical management
url http://www.dovepress.com/papilledema-epidemiology-etiology-and-clinical-management-peer-reviewed-article-EB
work_keys_str_mv AT rigim papilledemaepidemiologyetiologyandclinicalmanagement
AT almarzouqisj papilledemaepidemiologyetiologyandclinicalmanagement
AT morganml papilledemaepidemiologyetiologyandclinicalmanagement
AT leeag papilledemaepidemiologyetiologyandclinicalmanagement